- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02508701
A Pilot Study Comparing the Effectiveness of Campus Intervention to Increase HPV Vaccine Rate Among College Aged Men
A Pilot Study Comparing the Effectiveness of On-site Campus Interventions to Increase the Uptake of the HPV Three-shot Series Vaccine Among College Aged Men: A 2 X 2 Repeated Design
This is a study testing what type of message and access influences a young male to get the HPV vaccine.
The investigators are conducting a 2 X 2 design
These conditions are:
- Condition 1: Altruistic personal with direct recommendation inside-dorm
- Condition 2: Generic message with inside-dorm
- Condition 3: Generic message with outside-dorm HPV vaccine
- Condition 4: Altruistic personal with outside-dorm HPV vaccine
The objectives of this study are:
A. To examine the efficacy in encouraging young men to receive HPV shots at Time 1 within each of the four intervention conditions (altruistic/personal with direct recommendation vs. generic message) X (in-dorm vs. outside-dorm HPV vaccine).
B. To examine the efficacy in encouraging young men to receive HPV shots at Times 2 & 3 within each of the four intervention conditions (altruistic/personal with direct recommendation vs. generic message) X (in-dorm vs. outside-dorm HPV vaccine).
2.1.1 List the clinical hypotheses. Objective A H A.1: At Time 1, college men who have immediate access to the HPV vaccination will take the vaccination at a higher rate than those who do not have immediate access to the vaccine.
H A.2: At Time 1, college men who receive an altruistic/personal health message along with immediate access to the HPV vaccine will take the HPV vaccination at a higher rate than the men in the other three arms of the study.
Objective B H B.1: At Times 2 & 3, college men who have immediate access to the HPV vaccination will take the vaccination at a higher rate than those who do not have immediate access to the vaccine.
H B.2: At Times 2 & 3, college men who receive an altruistic/personal health message along with immediate access to the HPV vaccine will take the HPV vaccination at a higher rate than the men in the other three arms of the study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators will conduct an intervention on the Purdue campus targeting men-only dorm wings (living areas). Eight (8) dorm wings will be selected in advance.
Dorm wings will be randomly assigned to one of four intervention arms: (1) educational message with altruistic/personal health benefits emphasized along with a direct recommendation to get the vaccine along with immediate access to the vaccine with the dormitory (altruistic/personal benefit message with recommendation + in-dorm vaccine), (2) educational message with altruistic/personal health benefits emphasized along with information on where to go to get the vaccine (altruistic/personal benefit message with recommendation + outside-dorm vaccine) and (3) generic informational message about the HPV vaccine and immediate access to the vaccine in the dormitory (generic + on-site vaccine), (4) generic informational message with information on where to go to get the vaccine (generic + outside-dorm vaccine).
Phase 1 (Initial vaccine dose #1):
Recruitment of all four intervention arms will be occur at the same time during the dorm wing's first mandatory meetings for residents. These mandatory meetings occur throughout the campus. Fifty-two (52) residents live on each dorm wing and the first mandatory dorm meeting attendance is typically between 75-90% of all residents within the wing (between 47 and 52 men).
At the end of the mandatory wing meeting, a male research assistant will provide a brief presentation to the young men that describe the HPV vaccine (either altruistic/personal benefit message with recommendation or a generic message).
At the end of the brief presentation, residents will either be directed to the location where the HPV vaccine is set-up within the dormitory for immediate immunization (on-site vaccine) or provided a printed card that tells them how to get the vaccine on campus through the health center(outside-dorm vaccine). The location of the on-site vaccine will be close to the dorm wing.
Eligibility requirements will be determined at the site of the HPV vaccine by student health center staff members. These requirements are (over 18-years of age and have not received the three-shot series of the HPV vaccine).
For the on-site vaccine arms, once eligibility has been determined, research assistants will hand the young man over to the student health center staff (who will then conduct their typical vaccine protocol).
For those in the outside-dorm vaccine arms, students will go to the health center to receive the vaccine.
Phase 2 (2-month follow-up vaccine dose #2):
On-site vaccine arms. One week before the student health center staff will return to the dormitory for administer the second HPV dose, research assistants will contact participants by text and email to remind them of the follow-up. The investigators will also send a text message and email the night before. In addition, Resident Assistants will also be provided the name of the men in the study to remind participants of the returned visit the night before about the visit.
Outside-dorm vaccine. For those randomized to outside-dorm, research assistants will text and email participants one-week before their 2-month follow-up dose is needed. Resident Assistants will also be provided the name of the men in the study to remind participants about the getting the follow-up shot.
Phase 3: (6-month follow-up dose #3): The investigators will use the same protocol for the 6-month follow-up as the investigators use for the 2-month follow-up (reminder one week before and the night before using email, text, and resident assistants).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be young men between 18 to 21 years old
- live in one of the dorm floors in the study
Exclusion Criteria:
- Under 17 years old
- over 21 years old
- females
- young men that live outside the pre-identified dorm halls
- Also any young man with a moderate to severe illness will be excluded.
- anyone with a life threatening allergic reaction to components to the HPV vaccine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Altruistic inside-dorm
Altruistic & personal message with direct recommendation and access to the vaccine on-site The intervention is a message asking students to get the vaccine that tell students the vaccine is available in the dorm and provides a direct recommendation to get the vaccine |
Personal, Altruistic Message vs Generic Message Inside-Dormitory Vaccination vs. Student Health Center Vaccination
|
Other: Generic inside-dorm
Generic message and access to the vaccine on-site The intervention is a message asking students to get the vaccine that tell students the vaccine is available in the dorm but provides no recommendation |
Personal, Altruistic Message vs Generic Message Inside-Dormitory Vaccination vs. Student Health Center Vaccination
|
Other: Generic outside-dorm
Generic message and off-site access to the vaccine The intervention is a message asking students to get the vaccine that tell students the vaccine is available at the health center but provides no recommendation |
Personal, Altruistic Message vs Generic Message Inside-Dormitory Vaccination vs. Student Health Center Vaccination
|
Other: Altruistic outside-dorm
Altruistic & personal message with direct recommendation and off-site access to the vaccine The intervention is a message asking students to get the vaccine that tell students the vaccine is available at the student health center and provides a direct appeal to get the vaccine |
Personal, Altruistic Message vs Generic Message Inside-Dormitory Vaccination vs. Student Health Center Vaccination
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With 1st Uptake Shots
Time Frame: Up to 12 months
|
Number of Participants with the 1st Uptake Shots
|
Up to 12 months
|
Number of Participants With 1st Uptake Shot
Time Frame: 6 months
|
The Number of Participants with 1st Uptake Shot
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Second Uptake Shot
Time Frame: 6 months
|
6 months
|
|
Number of Participants With 3rd Uptake Shots
Time Frame: 6 months
|
The Number of Participants with 3rd Uptake Shots
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stewart C Chang Alexander, PhD, Purdue University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1506016224
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Papilloma Virus, Male
-
Regenstrief Institute, Inc.Merck Sharp & Dohme LLCCompletedCervical Cancer | Human Papilloma Virus Infection Type 11 | Human Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18 | Human Papilloma Virus Infection Type 6United States
-
Procare Health Iberia S.L.Adknoma Health ResearchCompletedHuman Papilloma Virus Infection | Human Papilloma Virus | Cervix LesionSpain
-
Emory UniversityNational Institute of Nursing Research (NINR)RecruitingHuman Papilloma Virus | Human Papilloma Virus VaccineUnited States
-
Vastra Gotaland RegionCompletedInfertility, Male | Human Papilloma VirusSweden
-
Louisiana State University Health Sciences Center...CompletedPapillomavirus Infections | Health Behavior | Attitude of Health Personnel | Human Papilloma Virus, MaleUnited States
-
Xiamen Innovax Biotech Co., LtdZhejiang Provincial Center for Disease Control and PreventionActive, not recruitingHuman Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18 | Hepatitis E Virus InfectionChina
-
The Behavioural Insights TeamUNICEF; National Center for Disease Control and Public Health, Georgia; Information...Not yet recruitingHPV, Human Papillomavirus Viruses, Human Papilloma Virus Vaccine
-
Universitair Ziekenhuis BrusselRecruiting
-
Universiti Sains MalaysiaRecruitingHuman Papilloma Virus InfectionMalaysia
-
Universiteit AntwerpenCompletedHuman Papilloma Virus InfectionBelgium
Clinical Trials on Message X Onsite/Offsite Vaccination
-
London School of Hygiene and Tropical MedicineWellcome Trust; National Health Service, United KingdomCompletedInfluenzaUnited Kingdom
-
Carnegie Mellon UniversityUniversity of Pennsylvania; Rutgers UniversityCompletedControl - No Incentive for Flu Vaccine | Direct Incentive | Indirect IncentiveUnited States
-
Johns Hopkins Bloomberg School of Public HealthBill and Melinda Gates Foundation; Direct Consulting and LogisticsCompletedLow Immunization UptakeNigeria